Skip to main content

Meet the Passionate
Individuals Behind Neurelis

Craig C. Chambliss

President and CEO/Co-Founder

C raig Chambliss has 25 years invested in the pharmaceutical, biotechnology, and drug delivery arenas, with primary focus on diseases of the central nervous system (CNS) and epilepsy, in particular. He co-founded Neurelis in 2007 and has served as CEO and President since 2013. 
In 2010, Mr. Chambliss joined NextWave Pharmaceuticals as Chief Business Officer and directed the corporate refocus to the CNS market, raising $45M in Series C financing and culminating in the sale of NextWave to Pfizer for over $700M in 2012. Prior to NextWave and Neurelis, he led commercial operations at Questcor Pharmaceuticals, from 2005-2007, where he was responsible for helping to engineer the transition to a CNS-focused company and establish the commercial infrastructure to support the relaunch of Acthar® Gel (repository corticotropin injection). 
Mr. Chambliss began his career in pharmaceutical sales at Bristol-Myers Squibb and joined Alza Pharmaceuticals upon the launch of their commercial organization in 1994. While at Alza Pharmaceuticals, he served in various sales and marketing roles prior to joining Elan Pharmaceuticals where he served as Director of Business Development for CNS assets. In 2001, along with other former Dura and Elan executives, Mr. Chambliss launched Xcel Pharmaceuticals, a CNS start-up focused on epilepsy and, primarily, the treatment of acute repetitive seizures. He led commercial operations and the successful launch of Diastat® (diazepam rectal gel) until Xcel's acquisition by Valeant Pharmaceuticals in 2005 for $280M. Mr. Chambliss holds a BS in Finance and a BS in Accounting from Missouri State University.

George Stuart

SVP and Chief Financial Officer

G eorge Stuart has 29 years of finance and accounting experience. The last 16 years have been spent within the specialty pharmaceutical and biotechnology industry. He has experience as a finance executive with both private and public companies and began his career in public accounting. He was an early investor in Neurelis and has been CFO since 2011. 
Since 2009, Mr. Stuart has provided finance-related consulting services to early-stage specialty pharmaceutical and biotech companies. Prior to 2009, he spent 3 years as the Senior Vice President and Chief Financial Officer of Questcor Pharmaceuticals where he led the move of Questcor's listing from the American to the NASDAQ exchange. In 2001, he helped launch Xcel Pharmaceuticals, a CNS start-up focused on epilepsy, and was its Vice President and Chief Financial Officer until its acquisition by Valeant Pharmaceuticals in 2005.
Mr. Stuart was the Director of Finance for Ligand Pharmaceuticals for 2 years prior to co-founding Xcel and began his career with Deloitte in 1986 where he last held the position of Senior Manager. He holds a BS in Accounting from San Diego State University.

Richard Lowenthal, MS, MSEL


M r. Richard Lowenthal possesses more than 25 years of experience in strategic drug development, project leadership, regulatory affairs, and quality assurance. Mr. Lowenthal has extensive experience with strategic global development as well as product registration of new drugs and biologics in the United States, Europe, and Japan. As founder of Pacific-Link Regulatory Consulting, Mr. Lowenthal is dedicated to the support of pharmaceutical, biotechnology, and investment companies, providing leadership and mentoring on regulatory affairs, clinical development, quality assurance, licensing, and investment opportunities. Mr. Lowenthal has led the regulatory efforts at Neurelis since its inception in 2007. 
Previously, Mr. Lowenthal has served as Vice President, Regulatory Affairs and Quality Assurance for Cadence Pharmaceuticals; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance of Somerset Pharmaceuticals Inc.; and as a New Drug Review Chemist for the US Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products.
Mr. Lowenthal holds an MS in Organic Chemistry from Florida State University and Masters in Business Science for Executive Leadership (MSEL) from the University of San Diego. Mr. Lowenthal has served as past Chair of the San Diego region for AAPS, as Member of the USP Biotechnology Expert Committee, Chair of the Virology Working group, Member of the National Organization of Rare Disease (NORD) Corporate Council, and with various PhARMA and ICH Working Groups.

Stuart Madden, PhD, CChem, FRSC

CMC/Scientific Affairs

L eading the CMC efforts at Neurelis since 2007, Dr. Stuart Madden is Vice President of Scientific Affairs at ICON Clinical Research, where he provides strategic consulting expertise to clients in optimizing their product development programs. Dr. Madden has more than 30 years’ experience in the pharmaceutical industry and, prior to joining ICON, held a number of positions with several international pharmaceutical companies, working on development programs from proof of concept through commercialization. His experience with a wide range of dosage forms, including specialized delivery systems and combination products for both small molecules and biologics, is combined with significant FDA regulatory experience to discuss and negotiate strategies with respect to drug product development programs.
Dr. Madden received his BS degree in Chemistry and his PhD in Physical Chemistry from the University of Wales, Swansea, UK and was a Post-Doctoral Fellow at San Diego State University for 2 years. Dr. Madden has published research in areas of adsorption mechanisms in chromatography and novel aspects of the degradation chemistry of morphine, has contributed to texts on In Vitro-In Vivo correlations, and has several patents approved/pending. He is a Chartered Chemist, a Fellow of the Royal Society of Chemistry, and a Special Government Employee consultant to FDA’s Pharmaceutical Science and Clinical Pharmacology Advisory Committee.


Lana Braverman, Pharm.D.

Senior Director of Medical

L ana Braverman, Pharm.D., has 18 years of pharmaceutical and biotechnology industry experience, working and specializing in various facets of medical affairs.
Ms. Braverman started her professional career in the Medical Information Department at INO Therapeutics. She then joined Bristol-Myers Squibb in global project management and, later, in medical review and leadership capacities.
Prior to joining Neurelis in 2017, Ms. Braverman spent 8 years at Acorda Therapeutics, where she served multiple roles within field medical functions, such as key opinion leader development, medical science liaison leadership and medical product/disease state knowledge leadership. While at Acorda, Ms. Braverman developed a wealth of neuroscience expertise, focused in multiple sclerosis, Parkinson’s disease, migraine, stroke, and epilepsy. Prior to departing from Acorda, she served as the Field Medical Lead for the company’s intranasal epilepsy product candidate.
Ms. Braverman holds a Doctor of Pharmacy degree from Rutgers University, College of Pharmacy, as well as a BS in Engineering from Kyiv National University of Technologies and Design (KNUTD).

Chuck DeWildt

Senior Vice President of Commercial and Market Access

C huck DeWildt has more than 25 years of experience in the pharmaceutical and biotechnology industry with specific experience in the central nervous system, respiratory, and oncology markets. He has served in leadership roles in sales, marketing, and market access.
Mr. DeWildt joined Neurelis from Teva, where he was Vice President of Market Access. His responsibilities included ensuring third-party patient access, leading Teva’s work with the integrated delivery/organized customer groups, implementing strategic employer initiatives, and ensuring targeted product reimbursement.
Mr. DeWildt joined Teva in 2011 as part of the company’s acquisition of Cephalon. Upon joining Cephalon in 1999, he served as a Strategic Healthcare Executive to assist in the launch of the CNS portfolio. Throughout his career at Cephalon, Mr. DeWildt held a variety of leadership positions in sales and market access, including serving as Head of Market Access and Reimbursement.
Mr. DeWildt began his career in pharmaceutical sales at DuPont Pharmaceuticals, where he served in various sales, clinical education, marketing, and market access roles. He holds a BA in Communications from the University of Wisconsin, Whitewater.

All trademarks are the property of their respective owners.